Conversely, we could leverage the OD-MS population for identifying new variants at risks for each tumor of the whole spectrum of IDH-mutated tumors, by comparing SNPs in OD-MS patients with versus without a specific tumor. This evidence concerns the gene IDH1 and neoplasm.